Breaking News Instant updates and real-time market news.

F

Ford

$8.90

-0.05 (-0.56%)

, GM

General Motors

$36.39

-0.23 (-0.63%)

17:50
11/19/19
11/19
17:50
11/19/19
17:50

Law experts say Trump can't impose 'Section 232' car tariffs, Reuters says

Trade law experts have said that time has run out on U.S. President Donald Trump's "Section 232" tariffs on imports of foreign-made cars and car parts, after the president finaled to announce a decision on the matter by a self-imposed deadline, Reuters' David Lawder reports. The White House may have to find another recourse if the president wishes to tax European or Japanese car imports, Lawder says, citing the experts. Publicly traded companies in the space include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

F

Ford

$8.90

-0.05 (-0.56%)

GM

General Motors

$36.39

-0.23 (-0.63%)

HMC

Honda

$28.73

-0.095 (-0.33%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$143.00

-0.53 (-0.37%)

TSLA

Tesla

$359.52

9.53 (2.72%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$15.59

-0.045 (-0.29%)

VWAGY

Volkswagen

$0.00

(0.00%)

  • 19

    Nov

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

F Ford
$8.90

-0.05 (-0.56%)

10/24/19
10/24/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ford (F) downgraded to Hold from Buy at Deutsche Bank with analyst Emmanuel Rosner saying he sees "continued earnings outlook deterioration" following Ford (F)'s Q3 results. 2. eBay (EBAY) downgraded to Market Perform from Outperform at Raymond James and to Hold from Buy at Aegis. 3. Cadence Bancorp (CADE) downgraded to Neutral from Overweight at JPMorgan and Piper Jaffray. 4. Ormat Technologies (ORA) downgraded to Market Perform from Outperform at Cowen. 5. iRobot (IRBT) downgraded to Neutral from Buy at BofA/Merrill with analyst John Babcock saying he reduced his estimates following iRobot's Q3 results and preliminary 2020 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/19
DBAB
10/24/19
DOWNGRADE
Target $11
DBAB
Hold
Deutsche Bank downgrades Ford on earnings outlook 'deterioration'
Deutsche Bank analyst Emmanuel Rosner downgraded d to Hold from Buy with a price target of $11, down from $12. The stock in premarket trading is down 4%, or 33c, to $8.88. The analyst sees "continued earnings outlook deterioration" following Ford's Q3 results. Operational issues, such as growing warranty and launch costs, along with pressures on U.S. pricing and China volumes continue to hurt the company's outlook, Rosner tells investors in a research note. Ford has a large opportunity in fixing its international operations, but the benefits from its $7B restructuring program will take longer than expected, contends the analyst.
10/24/19
DBAB
10/24/19
DOWNGRADE
DBAB
Hold
Ford downgraded to Hold from Buy at Deutsche Bank
11/19/19
MSCO
11/19/19
NO CHANGE
Target $46
MSCO
Overweight
GM could drive five-fold rise in Corvette volume with SUV, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said Ford's (F) decision to use its Mustang brand for the Mach-E electric SUV "stands as a clear precedent with relevance to Corvette" as he considers the potential of a hypothetical Corvette brand expansion into SUVs and battery electric vehicles as a way for General Motors (GM) to help fund the transition to electric, though he noted that the company has not confirmed any such plans. A hypothetical 100% electric Corvette SUV could drive a five- fold increase in volume to 80,000 units for Corvette by the mid 2020s, projects Jonas, who values the Corvette business at $7B in his base case scenario and at $12B in his bull case. He keeps an Overweight rating and $46 price target on GM shares.
GM General Motors
$36.39

-0.23 (-0.63%)

11/05/19
LEHM
11/05/19
DOWNGRADE
Target $12
LEHM
Equal Weight
Barclays downgrades American Axle on limited earnings upside
Barclays analyst Brian Johnson downgraded American Axle (AXL) to Equal Weight from Overweight with an unchanged price target of $12. The analyst appreciates the company's progress on operational performance and launch cost reduction, but he sees limited upside to 2020 earnings estimates. Johnson thinks there is "little reason to be Overweight the stock" given the limited upside to 2020 earnings expectations as a result of General Motors' (GM) capacity constraints and late-cycle nature and its exposure to U.S. automotive.
11/18/19
RBCM
11/18/19
NO CHANGE
Target $33
RBCM
Sector Perform
Navistar price target raised to $33 from $30 at RBC Capital
RBC Capital analyst Seth Weber raised his price target on Navistar (NAV) to $33 to reflect the multiple expansion across its peer group and calls the company's update last week regarding the impact of the GM (GM) autoworker strike as "unsurprising". The analyst notes that while the company projects its FY19 revenue and EBITDA to be at the low end of its prior guidance ranges, his FY20/21 estimates are "essentially unchanged", as he also maintains his Sector Perform rating on the stock.
11/19/19
BMOC
11/19/19
NO CHANGE
Target $30
BMOC
Market Perform
Navistar earnings forecasts lowered at BMO Capital
BMO Capital analyst Joel Tiss keeps his Market Perform rating and $30 price target on Navistar (NAV) after its reduced revenue and EBITDA guidance last week, but also lowers his FY19 and FY20 EPS views by 17c and 10c to $3.78 and $2.90 respectively. The analyst cites the impact of the 6-week labor strike at General Motors (GM) which prevented components from being delivered that led to the company's suspension of operations at its Springfield plant from late September to early November. Tiss adds that his reduced forecasts also assume potential production inefficiencies lingering into the start of the company's next fiscal year.
HMC Honda
$28.73

-0.095 (-0.33%)

06/19/19
UBSW
06/19/19
DOWNGRADE
UBSW
Neutral
Honda downgraded to Neutral from Buy at UBS
UBS analyst Kohei Takahashi downgraded Honda Motor to Neutral from Buy citing a lack of catalysts.
06/11/19
DBAB
06/11/19
UPGRADE
DBAB
Buy
Honda upgraded to Buy from Hold at Deutsche Bank
10/21/19
LYON
10/21/19
DOWNGRADE
LYON
Outperform
Honda downgraded to Outperform from Buy at CLSA
CLSA analyst Christopher Richter downgraded Honda to Outperform from Buy saying China is doing great, with double digit growth, but the rest of Asia is down in the double digits, and North America is struggling.
05/15/19
MSCO
05/15/19
NO CHANGE
MSCO
Tariff delay a 'modest positive' for automakers, says Morgan Stanley
Morgan Stanley analyst Michael Zezas called media reports indicating that the U.S. plans to delay auto tariffs by up to 6 months a "modest positive" for the automaking group, stating that extra time somewhat reduces the probability of tariffs going into place but that the core impasse between the U.S. and EU - namely whether or not to include agricultural issues in negotiations - still remains and is the real driver of the tariff tension. The analyst, who noted that the U.S. retains the option to implement tariffs at any point within the 180 day delay, said he still thinks auto tariffs are likely to go into effect later this year. Publicly traded automakers that moved up following the headlines regarding the delay decision include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM) and Volkswagen (VWAGY).
NSANY Nissan
$0.00

(0.00%)

05/14/19
MACQ
05/14/19
DOWNGRADE
MACQ
Underperform
Nissan downgraded to Underperform from Neutral at Macquarie
06/05/19
UBSW
06/05/19
UPGRADE
UBSW
Buy
Nissan upgraded to Buy from Sell at UBS
UBS upgraded Nissan to Buy from Sell and raised its price target on the shares to Y900 from Y800.
05/15/19
05/15/19
NO CHANGE

Trump plans to delay imposing tariffs on auto imports, Bloomberg reports
Publicly traded companies in the space include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM), Volkswagen (VWAGY) and Tesla (TLSA).
TM Toyota
$143.00

-0.53 (-0.37%)

06/07/19
BOFA
06/07/19
NO CHANGE
BOFA
Buy
Toyota 'clearly more focused' on China business, says BofA/Merrill
BofA/Merrill analyst Kei Nihonyanagi maintained a Buy rating and $140.98 price target on Toyota Motor (TM) following The Nikkei's report that the automaker will partner with China's CATL, an automotive battery maker. In a research note to investors, the analyst says the report is somewhat "surprising," given Toyota announced a JV with Panasonic (PCRFY) earlier this year to produce automotive batteries for electric vehicles, but says Toyota is "clearly more focused" on its China business than before.
09/05/19
MSCO
09/05/19
DOWNGRADE
MSCO
Underweight
Toyota downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded Toyota to Underweight, stating that the company's pivot to becoming a "new mobility leader" as announced early last year will come with higher R&D costs, lower margins, and lower free cash flows relative to consensus expectations. Morgan Stanley contends that "the market continues to underestimate the cost of transformation", adding that its value premium over other automakers will shrink over time.
TSLA Tesla
$359.52

9.53 (2.72%)

11/13/19
MSCO
11/13/19
NO CHANGE
Target $250
MSCO
Equal Weight
Tesla gross margins in China may 'push the mid-30% range,' says Morgan Stanley
Morgan Stanley analyst Adam Jonas said labor costs for Tesla in China could be one-tenth of what they are for the company in California and he feels that many investors do not fully appreciate that Tesla is about to address both the largest electric vehicle and luxury car markets in the world, both of which are in China, "at scale and at a more advantageous cost basis." At the midpoint of his estimates, Jonas sees the potential for low to mid-30% auto gross margins in China for Tesla, he tells investors. He believes that Tesla vehicles could theoretically add about $4.00 to his estimates for 2022 EPS, or roughly $60 to Tesla shares at a 15 times P/E multiple, Jonas added. The analyst, who thinks the Shanghai Gigafactory has potential to be one of the more profitable auto factories in the world, keeps an Equal Weight rating and $250 price target on Tesla shares.
11/12/19
MSCO
11/12/19
NO CHANGE
Target $250
MSCO
Equal Weight
Tesla may be entering 'hottest, fastest growing' EV segment, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said Tesla's planned pickup truck unveiling event on November 21 could be "the beginning of a process that may see Tesla potentially more than triple its model line-up" by 2025 and multiply its segment coverage by a factor of five in the process. Pickup trucks may arguably, along with delivery vans, become the "hottest, fastest growing EV" segment in the U.S. market over the next 3 to 5 years, contends Jonas, who questions if the short term noise around Tesla may have diverted attention from the potential for the upcoming "Cyberpunk" pickup. Jonas keeps an Equal Weight rating and $250 price target on Tesla shares.
11/18/19
DBAB
11/18/19
NO CHANGE
Target $290
DBAB
Hold
Tesla price target raised to $290 from $260 at Deutsche Bank
Deutsche Bank analyst Emmanuel Rosner raised his price target for Tesla to $290 from $260 while keeping a Hold rating on the shares. Tesla is set to unveil its "Cybertruck" electric pickup on November 21, and assuming most performance specifications are in line with those teased over time by Elon Musk, the focus will likely be on how well the actual design resonates with pickup buyers, Rosner tells investors in a research note. Based on Musk's comments that the truck "looks like an armored personnel carrier from the future," and is "unrecognizable from the trucks from the past 20-40 years," the analyst sees risk of the truck not attracting traditional pickup buyers, "leaving it a lower-volume niche product."
11/11/19
JEFF
11/11/19
NO CHANGE
Target $400
JEFF
Buy
Tesla price target raised to $400 from $300 at Jefferies
Jefferies analyst Philippe Houchois raised his price target for Tesla to $400 from $300 saying the company's risk profile continues to improve. The stock closed Friday Tesla's gross margin levels in Q3 are consistent with sustained profitability and its average selling prices should stabilize ahead of improvements in the second half of 2020, Houchois tells investors in a research note. Stabilization in 2019 "sets a better foundation" for a return to growth in 2020 revenue and earnings, adds the analyst. Houchois, who continues to see Tesla maintaining its edge in product, affordability and technology, keeps a Buy rating on the shares.
DDAIF Daimler AG
$0.00

(0.00%)

11/15/19
EXAN
11/15/19
DOWNGRADE
EXAN
Neutral
Daimler AG downgraded to Neutral from Outperform at Exane BNP Paribas
Exane BNP Paribas analyst Stuart Pearson downgraded Daimler AG to Neutral from Outperform with a price target of 53 euros.
10/07/19
HSBC
10/07/19
UPGRADE
HSBC
Hold
Daimler AG upgraded to Hold from Reduce at HSBC
HSBC analyst Henning Cosman upgraded Daimler AG to Hold from Reduce with a price target of 45 euros, down from 46 euros.
09/03/19
UBSW
09/03/19
UPGRADE
UBSW
Buy
Daimler AG upgraded to Buy from Neutral at UBS
UBS upgraded Daimler AG to Buy from Neutral.
08/05/19
JEFF
08/05/19
DOWNGRADE
JEFF
Underperform
Daimler AG downgraded to Underperform from Hold at Jefferies
Jefferies analyst Philippe Houchois downgraded Daimler AG to Underperform from Hold and lowered his price target for the shares to 40 euros from 50 euros. The analyst sees "unclear compliance roadmaps, below normal average earnings and balance sheet risk on potential cash burn."
FCAU Fiat Chrysler
$15.59

-0.045 (-0.29%)

11/01/19
REDB
11/01/19
UPGRADE
REDB
Neutral
Fiat Chrysler upgraded to Neutral from Sell at Redburn
Redburn analyst Charles Coldicott upgraded Fiat Chrysler to Neutral from Sell.
11/04/19
HSBC
11/04/19
UPGRADE
HSBC
Buy
Fiat Chrysler upgraded to Buy from Hold at HSBC
HSBC analyst Giulio Pescatore upgraded Fiat Chrysler to Buy from Hold.
11/18/19
DBAB
11/18/19
DOWNGRADE
DBAB
Hold
Peugeot downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Gaetan Toulemonde downgraded Peugeot (PUGOY) to Hold from Buy with a price target of 26 euros, down from 28 euros. The analyst believes Peugeot shareholders are "taking all of the risks" in the proposed merger with Fiat Chrysler (FCAU).
11/12/19
EXAN
11/12/19
UPGRADE
Target $19.3
EXAN
Outperform
Fiat Chrysler upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Stuart Pearson upgraded Fiat Chrysler to Outperform from Neutral with a price target of $19.30.
VWAGY Volkswagen
$0.00

(0.00%)

09/10/19
DZBN
09/10/19
DOWNGRADE
DZBN
Sell
Volkswagen downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Michael Punzet downgraded Volkswagen to Sell from Hold and lowered his price target for the shares to 120 euros from 147 euros.
08/27/19
LOOP
08/27/19
NO CHANGE
Target $38
LOOP
Buy
Navistar price target lowered to $38 from $44 at Loop Capital
Loop Capital analyst Jeffrey Kauffman lowered his price target on Navistar (NAV) to $38 as part of a "sector call" to reflect his lowered outlook for the trucking industry in 2020-2021. The analyst is also keeping his Buy rating on the stock, saying the company's market share gains, new products, and operating improvements should "dampen" the headwinds of a Class 8 trucking market peak. Kauffman contends that Navistar is "unique" thanks to its partnership with Volkswagen (VWAGY), adding that his expected 25% improvement in market share should offset the 20%-25% pullback in sector volume activity.
10/10/19
GSCO
10/10/19
INITIATION
GSCO
Buy
Volkswagen initiated with a Buy rating at Goldman Sachs
Goldman Sachs analyst George Galliers started Volkswagen with a Buy rating and 193 euros price target. The analyst believes Volkswagen "offers more optionality" than any other company in his coverage. The company's electrification opportunity could add an incremental 2B euros of earnings in 2022 in a "Blue Sky" scenario, Galliers tells investors in a research note.
09/04/19
JPMS
09/04/19
INITIATION
JPMS
Overweight
Volkswagen resumed with an Overweight at JPMorgan
JPMorgan analyst Jose Asumendi assumed coverage of Volkswagen with an Overweight rating and price target of 176 euros. The analyst expects the company's product cycle to start gaining momentum.

TODAY'S FREE FLY STORIES

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.